Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. PD-L1 compound III-5
- Development stage
- Unknown
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. PD-L1 compound III-5: sourced facts only. name: "These findings suggest that compound III-5 holds promise as an inhibitor of the PD-1/PD-L1 interaction for cancer immunotherapy." [PMID:39278065]; target: "These findings suggest that compound III-5 holds promise as an inhibitor of the PD-1/PD-L1 interaction for cancer immunotherapy." [PMID:39278065]; developer: "Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China." [PMID:39278065]; stage: "Moreover, compound III-5, an ester prodrug derived from III-4, demonstrated significant antitumor effects in the hPD-L1-MC38 C57BL/6 mouse model (TGI: 49.6 %) by oral administration." [PMID:39278065]
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on China Pharma Univ. PD-L1 compound III-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. PD-L1 compound III-5.